EQS-News

DEFENCE’S ACCUM-mRNA LIPID NANOPARTICLES ELICIT ANTIBODY RESPONSE 2X STRONGER THAN STANDARD mRNA VACCINES

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE’S ACCUM-mRNA LIPID NANOPARTICLES ELICIT ANTIBODY RESPONSE 2X STRONGER THAN STANDARD mRNA VACCINES 25.09.2023 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement.

_________________________________________________________________

CSE: DTC  FSE: DTC  USOTC: DTCFF        PRESS RELEASE

 

 

DEFENCE’S ACCUM-mRNA LIPID NANOPARTICLES ELICIT ANTIBODY RESPONSE 2X STRONGER THAN STANDARD mRNA VACCINES

 

Vancouver, BC, Canada, September 25^th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that its encapsulation strategy used to generate Accum-mRNA lipid nanoparticles (LNPs) results in an antibody response that is twice as potent as standard mRNA LNPs. These results constitute a strong basis for conducting additional tests to optimize Defence’s mRNA vaccine pipeline.  

 

This in vivo study had two main objectives: testing multiple LNP formulations and comparing their induced immune responses to standard mRNA. All vaccines were delivered as part of a prime-boost vaccination protocol with animal bleeding performed every two weeks over a total period of 4 weeks and antibody titers quantified by ELISA. Amongst the tested groups, one Accum-containing LNP formulation stood-up triggering a higher antibody compared to the remaining groups. 

 

“The use of mRNA vaccines now expanding rapidly into cancer therapeutics will expand exponentially over the next decade due to their established potency and ease of manufacturing. Defence will thus strive in applying its platform of Accum technology in mRNA vaccination opportunities, which will have a great impact on the induced immune responses”, says Mr. Plouffe, CEO of Defence Therapeutics.